Siddharth Mittal, CEO and Managing Director of Biocon Limited, commented on the implications of US President Donald Trump's recent decision to impose a 100% tariff on patented pharmaceutical imports. He noted that this move is unlikely to disrupt Indian drugmakers significantly in the short term, as it predominantly targets branded medicines while exempting generics and biosimilars. This exemption provides a buffer for India's pharmaceutical exports, which are crucial to the US market where Indian companies hold a substantial share in the generics sector. However, Mittal expressed concern over rising protectionism in global trade, indicating that while immediate impacts are limited, the broader trend could pose challenges for the industry in the future. He also highlighted ongoing issues such as increasing logistics and supply chain costs due to geopolitical tensions, which could further complicate the sector's operations. Looking ahead to the financial year 2027, Mittal remains cautiously optimistic about strong global demand for pharmaceuticals, particularly generics and biosimilars, while emphasizing the need for Indian companies to adapt to changing trade policies and manage cost pressures.